论文部分内容阅读
For breast cancer patients with lymph node metastasis, paclitaxel is the first-lin e chemotherapy drug.Clinical studies showed that some patients with breast cancer were i nsensitive to paclitaxel, which led to chemotherapy failure.Today, no validated markers ex ist for prediction of chemotherapy sensitivity in this patient group.Tissue inhibitor of met alloproteinases-1 (TIMP-1) has been shown to protect against apoptosis.Epidemiological st udies have also associated elevated tumor tissue TIMP-1 levels with a poor response to cy clophosphamide/methotrexate/5-fluorouracil and anthracycline-based chemotherapy.Additional ly, our previous study proved that TIMP-1 significantly decreased the sensitivity of breast cancer cells to paclitaxel-induced apoptosis by enhancing degradation of cyclin B1.These data imply that TIMP-1 may be a useful predictive biomarker for chemotherapy resistance.